Breaking News, Collaborations & Alliances

SignalRx, Crystec and ADYA Partner to Develop Treatment for SARS-CoV-2 Related Illnesses

Aim to develop an inhaled dry powder formulation of SF2523.

Author Image

By: Charlie Sternberg

Associate Editor

SignalRx Pharmaceuticals Inc., Crystec Ltd. and ADYA Consulting SAGL have entered a new collaboration to develop an inhaled dry powder formulation of SF2523 for the treatment of pulmonary fibrosis, lung cancer and SARS-CoV-2 related illnesses.   SignalRx SF2523 is a novel, small molecule dual PI3K-BRD4 inhibitor with a synergistic action on two pathways associated with the development of lung cancer and idiopathic pulmonary fibrosis (IPF). Combined inhibition of both the PI3K and BRD4 pathways m...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters